H. Lundbeck Dividenden en inkoop

Dividend criteriumcontroles 3/6

H. Lundbeck is een dividendbetalend bedrijf met een huidig rendement van 1.57% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

1.6%

Dividendrendement

0.1%

Terugkoop Rendement

Totaal aandeelhoudersrendement	1.7%
Toekomstig dividendrendement	2.8%
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	US$0.101
Uitbetalingsratio	26%

Recente updates van dividend en inkoop

Recent updates

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Hoewel de dividendbetalingen stabiel zijn, betaalt HLUB.F nog geen 10 jaar dividend uit.

Groeiend dividend: De dividendbetalingen van HLUB.F zijn gestegen, maar het bedrijf heeft pas 2 jaar dividend uitgekeerd.

Dividendrendement versus markt

H. Lundbeck Dividendrendement versus markt

Hoe verhoudt HLUB.F dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (HLUB.F)	1.6%
Markt onderkant 25% (US)	1.4%
Markt Top 25% (US)	4.3%
Gemiddelde industrie (Pharmaceuticals)	2.5%
Analist prognose (HLUB.F) (tot 3 jaar)	2.8%

Opmerkelijk dividend: Het dividend van HLUB.F ( 1.57% ) is hoger dan dat van de onderste 25% van de dividendbetalers op de US markt ( 1.39% ).

Hoog dividend: Het dividend HLUB.F ( 1.57% ) is laag vergeleken met de top 25% van dividendbetalers in de US markt ( 4.32% ).

Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn redelijk lage payout ratio ( 25.8% ) worden de dividendbetalingen van HLUB.F ruimschoots gedekt door de winst.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn lage cash payout ratio ( 14.1% ) worden de dividendbetalingen van HLUB.F volledig gedekt door kasstromen.

H. Lundbeck Dividenden en inkoop

Dividend criteriumcontroles 3/6

Belangrijke informatie

Recente updates van dividend en inkoop

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Proposes Dividend for 2022

Recent updates

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend